acetaminophen has been researched along with Obesity, Morbid in 16 studies
Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.
paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.
Obesity, Morbid: The condition of weighing two, three, or more times the ideal weight, so called because it is associated with many serious and life-threatening disorders. In the BODY MASS INDEX, morbid obesity is defined as having a BMI greater than 40.0 kg/m2.
Excerpt | Relevance | Reference |
---|---|---|
"PONV was assessed in recovery and 24 hours after surgery in the ward." | 7.01 | Prophylactic Administration of Diphenhydramine/Acetaminophen and Ondansetron Reduced Postoperative Nausea and Vomiting and Pain Following Laparoscopic Sleeve Gastrectomy: a Randomized Controlled Trial. ( Aghabagheri, M; Khajavi, MR; Najjari, K; Pourfakhr, P; Talebpour, M; Zabihi Mahmoudabadi, H, 2021) |
" Bariatric surgery resulted in faster absorption and normalized pharmacokinetic parameters, prompting an increase in paracetamol bioavailability." | 6.84 | Pharmacokinetics in Morbid Obesity: Influence of Two Bariatric Surgery Techniques on Paracetamol and Caffeine Metabolism. ( Boix, DB; Civit, E; de la Torre, R; Farré, M; Goday Arno, A; Grande, L; Langohr, K; Le Roux, JAF; Lí Carbó, M; Nino, OC; Papaseit, E; Pera, M; Pérez-Mañá, C; Ramon, JM; Rodríguez-Morató, J, 2017) |
" The protocol utilized oral celecoxib and scheduled oral acetaminophen for pain control, with opioids used only as needed for breakthrough pain." | 3.91 | Multimodal Postoperative Pain Control Is Effective and Reduces Opioid Use After Laparoscopic Roux-en-Y Gastric Bypass. ( Dove, J; Fluck, M; Gabrielsen, JD; Gionfriddo, MR; Horsley, RD; McField, DAP; Medico, C; Parker, DM; Petrick, AT; Vogels, ED, 2019) |
"PONV was assessed in recovery and 24 hours after surgery in the ward." | 3.01 | Prophylactic Administration of Diphenhydramine/Acetaminophen and Ondansetron Reduced Postoperative Nausea and Vomiting and Pain Following Laparoscopic Sleeve Gastrectomy: a Randomized Controlled Trial. ( Aghabagheri, M; Khajavi, MR; Najjari, K; Pourfakhr, P; Talebpour, M; Zabihi Mahmoudabadi, H, 2021) |
" In a simulation of expected steady-state plasma concentrations following multiple dosing of 650 mg APAP every 4 hours, post-RYGBS patients had higher steady-state peak APAP concentrations compared to healthy individuals and obese pre-RYGBS patients, though APAP exposure was unchanged compared to healthy individuals." | 2.94 | The Impact of Proximal Roux-en-Y Gastric Bypass Surgery on Acetaminophen Absorption and Metabolism. ( Chan, LN; Chen, KF; Flum, DR; Horn, JR; Lin, YS; Oelschlager, BK; Senn, TD; Shen, DD, 2020) |
"We also aimed to compare postoperative pain levels and side effects of the drugs." | 2.87 | Comparison of intravenous ibuprofen and acetaminophen for postoperative multimodal pain management in bariatric surgery: A randomized controlled trial. ( Erdogan Kayhan, G; Kirteke, R; Ozgul, U; Sanli, M; Yologlu, S, 2018) |
" Bariatric surgery resulted in faster absorption and normalized pharmacokinetic parameters, prompting an increase in paracetamol bioavailability." | 2.84 | Pharmacokinetics in Morbid Obesity: Influence of Two Bariatric Surgery Techniques on Paracetamol and Caffeine Metabolism. ( Boix, DB; Civit, E; de la Torre, R; Farré, M; Goday Arno, A; Grande, L; Langohr, K; Le Roux, JAF; Lí Carbó, M; Nino, OC; Papaseit, E; Pera, M; Pérez-Mañá, C; Ramon, JM; Rodríguez-Morató, J, 2017) |
"Using IV acetaminophen for postoperative pain management produced notable indirect cost savings and reduced ED visits in the first 30 days postoperatively, with good safety and tolerance." | 2.82 | IV Acetaminophen Results in Lower Hospital Costs and Emergency Room Visits Following Bariatric Surgery: a Double-Blind, Prospective, Randomized Trial in a Single Accredited Bariatric Center. ( Claros, L; El Chaar, M; Stoltzfus, J; Wasylik, T, 2016) |
" The aim of this study was to better understand the drug-drug interaction (DDI) potential of CYP3A and P-gp inhibitors." | 1.56 | PBPK modeling of CYP3A and P-gp substrates to predict drug-drug interactions in patients undergoing Roux-en-Y gastric bypass surgery. ( Chan, LN; Chen, KF; Lin, YS, 2020) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 11 (68.75) | 24.3611 |
2020's | 5 (31.25) | 2.80 |
Authors | Studies |
---|---|
Chen, KF | 2 |
Chan, LN | 2 |
Senn, TD | 1 |
Oelschlager, BK | 1 |
Flum, DR | 1 |
Shen, DD | 1 |
Horn, JR | 1 |
Lin, YS | 2 |
Shaheed, CA | 1 |
Ferreira, GE | 1 |
Maher, CG | 1 |
Abusabeib, A | 1 |
El Ansari, W | 1 |
Alobaidan, J | 1 |
Elhag, W | 1 |
Pourfakhr, P | 1 |
Aghabagheri, M | 1 |
Zabihi Mahmoudabadi, H | 1 |
Najjari, K | 1 |
Talebpour, M | 1 |
Khajavi, MR | 1 |
Goday Arno, A | 1 |
Farré, M | 2 |
Rodríguez-Morató, J | 2 |
Ramon, JM | 1 |
Pérez-Mañá, C | 2 |
Papaseit, E | 1 |
Civit, E | 1 |
Langohr, K | 2 |
Lí Carbó, M | 1 |
Boix, DB | 1 |
Nino, OC | 1 |
Le Roux, JAF | 1 |
Pera, M | 1 |
Grande, L | 1 |
de la Torre, R | 2 |
Goday, A | 1 |
Ferreira, V | 1 |
Wang, JJ | 1 |
Villeneuve, E | 1 |
Gosselin, S | 1 |
Reith, DM | 1 |
van Rongen, A | 2 |
Välitalo, PAJ | 2 |
Knibbe, CAJ | 2 |
Erdogan Kayhan, G | 1 |
Sanli, M | 1 |
Ozgul, U | 1 |
Kirteke, R | 1 |
Yologlu, S | 1 |
Cooke, FE | 1 |
Samuels, JD | 1 |
Pomp, A | 1 |
Gadalla, F | 1 |
Wu, X | 1 |
Afaneh, C | 1 |
Dakin, GF | 1 |
Goldstein, PA | 1 |
Horsley, RD | 1 |
Vogels, ED | 1 |
McField, DAP | 1 |
Parker, DM | 1 |
Medico, C | 1 |
Dove, J | 1 |
Fluck, M | 1 |
Gabrielsen, JD | 1 |
Gionfriddo, MR | 1 |
Petrick, AT | 1 |
Lee, Y | 1 |
Yu, J | 1 |
Doumouras, AG | 1 |
Ashoorion, V | 1 |
Gmora, S | 1 |
Anvari, M | 1 |
Hong, D | 1 |
Peeters, MYM | 1 |
Boerma, D | 1 |
Huisman, FW | 1 |
van Ramshorst, B | 1 |
van Dongen, EPA | 1 |
van den Anker, JN | 1 |
El Chaar, M | 1 |
Stoltzfus, J | 1 |
Claros, L | 1 |
Wasylik, T | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Pharmacokinetics in Morbid Obesity: Influence of Two Bariatric Surgery Techniques in Drugs Metabolism.[NCT01086722] | Phase 1/Phase 2 | 52 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
Pharmacokinetics and Safety of Treatment With Paracetamol in Children and Adults With Spinal Muscular Atrophy and Cerebral Palsy[NCT03648658] | Phase 4 | 48 participants (Anticipated) | Interventional | 2019-02-18 | Recruiting | ||
Role of Scheduled Intravenous Acetaminophen for Postoperative Pain Management in an Enhanced Recovery After Surgery (ERAS) Population: A Prospective, Randomized, Double-Blind and Placebo-Controlled Clinical Trial[NCT03198871] | Phase 4 | 180 participants (Actual) | Interventional | 2018-05-24 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Number of patients who score greater than a 4 on the 0-8 point ICDSC scale to assess delirium scores. 8 separate levels of signs for delirium assessed (1. altered level of consciousness, 2. inattention, 3. disorientation, 4. hallucination, delusion, or psychosis, 5. psychomotor agitation or retardation, 6. inappropriate speech or mood, 7. sleep-wake cycle disturbance, 8. symptom fluctuation), with 0 points awarded when patient does not exhibit above signs of delirium and 1 point awarded per confirmed sign of delirium. Score then totaled, 0 = normal, 1-3 = subsyndromal delirium, 4-8 = delirium. (NCT03198871)
Timeframe: The delirium scores will first be measured every 12 hours for 72 hours after surgery.
Intervention | Participants (Count of Participants) |
---|---|
Acetaminophen Injectable Product | 0 |
Sodium Chloride 0.9%, Intravenous | 0 |
If the patient is readmitted to the hospital after being fully discharged, the event will be recorded. (NCT03198871)
Timeframe: From the time of consent until 30 days post-operatively
Intervention | Participants (Count of Participants) |
---|---|
Acetaminophen Injectable Product | 9 |
Sodium Chloride 0.9%, Intravenous | 10 |
Number of patients with unsatisfactory pain relief defined as average numeric rating scale (NRS) more than 5 will be compared between the two groups. This may include patients using IVPCA for pain relief during the first 48 hours postoperative. (NCT03198871)
Timeframe: PACU admission every thirty minutes until discharge to the floor and thereafter every four hours for first 24-hour, then every six hours until 48 hours and then every twelve hours until 72 hours postoperatively.
Intervention | Participants (Count of Participants) |
---|---|
Acetaminophen Injectable Product | 33 |
Sodium Chloride 0.9%, Intravenous | 42 |
The time it takes for the patient to successfully ambulate post-surgery will be measured. (NCT03198871)
Timeframe: From date of PACU admission until the date of first documented ambulation, assessed up to 72 hours postoperatively
Intervention | hours (Median) |
---|---|
Acetaminophen Injectable Product | 18.82 |
Sodium Chloride 0.9%, Intravenous | 17.38 |
The time it takes for the first bowel movement postoperatively will be measured. (NCT03198871)
Timeframe: From time patient left operating room until the time of first documented bowel movement, assessed up to hospital discharge
Intervention | hours (Median) |
---|---|
Acetaminophen Injectable Product | 46.30 |
Sodium Chloride 0.9%, Intravenous | 64.66 |
The time it takes for the patient to be fully discharged from the hospital post-surgery will be measured. (NCT03198871)
Timeframe: From date of randomization until the date of hospital discharge or 30 days postoperatively, whichever comes first
Intervention | days (Median) |
---|---|
Acetaminophen Injectable Product | 4.08 |
Sodium Chloride 0.9%, Intravenous | 4.94 |
The time it takes for the patient to ingest orally post-surgery will be measured. (NCT03198871)
Timeframe: From date of randomization until the date of first documented oral intake, assessed up to 72 hours postoperatively
Intervention | hours (Median) |
---|---|
Acetaminophen Injectable Product | 12.15 |
Sodium Chloride 0.9%, Intravenous | 9.40 |
The time from PACU admission to PACU discharge to the floor will be measured. (NCT03198871)
Timeframe: From time of PACU admission until the time of discharge, assessed up to 24 hours postoperatively
Intervention | minutes (Median) |
---|---|
Acetaminophen Injectable Product | 129.00 |
Sodium Chloride 0.9%, Intravenous | 152.50 |
Overall patient satisfaction as well as satisfaction relating to pain management and cost analyses will be measured. These will be measured with a numerical rating scale (NRS) with 0- being worst satisfaction and 10 - best satisfaction. (NCT03198871)
Timeframe: These measurements will be taken at time of discharge up to 30 days, whichever comes first
Intervention | score on a scale (Median) | |
---|---|---|
Patient satisfaction score, overall | Patient Satisfaction score, pain management | |
Acetaminophen Injectable Product | 10 | 10 |
Sodium Chloride 0.9%, Intravenous | 10 | 10 |
Frequency of emesis and rescue antiemetic requirement will be documented (NCT03198871)
Timeframe: These will be evaluated from the time of PACU admission until 72 hours postoperatively.
Intervention | Participants (Count of Participants) | |
---|---|---|
Emesis incidence 0-72 hours | Antiemetic use | |
Acetaminophen Injectable Product | 12 | 31 |
Sodium Chloride 0.9%, Intravenous | 14 | 45 |
Nausea will be evaluated by nausea score from 0 to 10, with 0 equaling no nausea and 10 equaling the worst nausea imaginable. (NCT03198871)
Timeframe: These will be evaluated from the time of PACU admission until 72 hours postoperatively.
Intervention | score on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Nausea score POD 1 (am visit) | Nausea score POD 1 (pm visit) | Nausea score POD 2 (am visit) | Nausea score POD 2 (pm visit) | Nausea score POD 3 (am visit) | Nausea score POD 3 (pm visit) | |
Acetaminophen Injectable Product | 1.13 | 0.49 | 0.71 | 0.55 | 0.32 | 0.56 |
Sodium Chloride 0.9%, Intravenous | 0.60 | 0.92 | 0.75 | 0.69 | 0.66 | 0.78 |
Survey to assess patient's overall health (via a combination of mental and physical health assessment) at 30 days post-discharge. Two summary scores are reported from the SF-12 - a mental component score (MCS-12) and a physical component score (PCS-12). The scores may be reported as Z-scores (difference compared to the population average, measured in standard deviations). The United States population average PCS-12 and MCS-12 are both 50 points. The United States population standard deviation is 10 points. So each 10 increment of 10 points above or below 50, corresponds to one standard deviation away from the average (NCT03198871)
Timeframe: These measurements will take place at 30-days post hospital discharge
Intervention | Z-scores (difference compared to the pop (Median) | |
---|---|---|
SF 12 Physical score | SF 12 Mental score | |
Acetaminophen Injectable Product | 38.72 | 54.02 |
Sodium Chloride 0.9%, Intravenous | 38.07 | 52.08 |
Rescue analgesia will be given according to institutional pain management protocol. Unit of Measure recorded as OME (Oral Morphine Equivalent) consumption in mg. (NCT03198871)
Timeframe: From time of PACU admission until the time of discharge and 72-hours postoperatively, whichever comes first
Intervention | mg (Median) | ||||
---|---|---|---|---|---|
0-24 hours | 24-48 hours | 48-72 hours | 0-48 hours | 0-72 hours | |
Acetaminophen Injectable Product | 27.4 | 31.3 | 30 | 74 | 105.00 |
Sodium Chloride 0.9%, Intravenous | 36 | 45 | 37.5 | 88.8 | 127.1 |
1 review available for acetaminophen and Obesity, Morbid
Article | Year |
---|---|
Intravenous Acetaminophen Versus Placebo in Post-bariatric Surgery Multimodal Pain Management: a Meta-analysis of Randomized Controlled Trials.
Topics: Acetaminophen; Administration, Intravenous; Analgesics; Bariatric Surgery; Humans; Obesity, Morbid; | 2019 |
6 trials available for acetaminophen and Obesity, Morbid
Article | Year |
---|---|
The Impact of Proximal Roux-en-Y Gastric Bypass Surgery on Acetaminophen Absorption and Metabolism.
Topics: Acetaminophen; Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curv | 2020 |
Prophylactic Administration of Diphenhydramine/Acetaminophen and Ondansetron Reduced Postoperative Nausea and Vomiting and Pain Following Laparoscopic Sleeve Gastrectomy: a Randomized Controlled Trial.
Topics: Acetaminophen; Antiemetics; Diphenhydramine; Double-Blind Method; Gastrectomy; Humans; Laparoscopy; | 2021 |
Pharmacokinetics in Morbid Obesity: Influence of Two Bariatric Surgery Techniques on Paracetamol and Caffeine Metabolism.
Topics: Acetaminophen; Adolescent; Adult; Bariatric Surgery; Biomarkers; Caffeine; Female; Gastrectomy; Gast | 2017 |
Comparison of intravenous ibuprofen and acetaminophen for postoperative multimodal pain management in bariatric surgery: A randomized controlled trial.
Topics: Acetaminophen; Administration, Intravenous; Adult; Analgesia, Patient-Controlled; Analgesics, Opioid | 2018 |
A Randomized, Double-Blind, Placebo-Controlled Trial of Intravenous Acetaminophen on Hospital Length of Stay in Obese Individuals Undergoing Sleeve Gastrectomy.
Topics: Acetaminophen; Administration, Intravenous; Analgesics, Non-Narcotic; Double-Blind Method; Gastrecto | 2018 |
IV Acetaminophen Results in Lower Hospital Costs and Emergency Room Visits Following Bariatric Surgery: a Double-Blind, Prospective, Randomized Trial in a Single Accredited Bariatric Center.
Topics: Acetaminophen; Administration, Intravenous; Adult; Analgesics, Non-Narcotic; Double-Blind Method; Em | 2016 |
9 other studies available for acetaminophen and Obesity, Morbid
Article | Year |
---|---|
Correction to Meta-analysis of Intravenous Acetaminophen (paracetamol) Versus Placebo Post-bariatric Surgery.
Topics: Acetaminophen; Bariatric Surgery; Humans; Obesity, Morbid; Pain, Postoperative; Randomized Controlle | 2020 |
PBPK modeling of CYP3A and P-gp substrates to predict drug-drug interactions in patients undergoing Roux-en-Y gastric bypass surgery.
Topics: Acetaminophen; Administration, Oral; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B | 2020 |
First Case Report of Fulminant Hepatitis After Laparoscopic Sleeve Gastrectomy Associated with Concomitant Maximal Therapeutic Dose of Acetaminophen Use, Protein Calorie Malnutrition, and Vitamins A and D, Selenium, and Glutathione Deficiencies.
Topics: Acetaminophen; Gastrectomy; Glutathione; Humans; Laparoscopy; Massive Hepatic Necrosis; Obesity, Mor | 2021 |
Answer to the Letter to the Editor Concerning "Pharmacokinetics in Morbid Obesity: Influence of Two Bariatric Surgery Techniques on Paracetamol and Caffeine Metabolism".
Topics: Acetaminophen; Bariatric Surgery; Caffeine; Gastric Bypass; Humans; Obesity, Morbid | 2017 |
Letter in Reply to Arno et al. "Pharmacokinetics in Morbid Obesity: Influence of Two Bariatric Surgery Techniques on Paracetamol and Caffeine Metabolism".
Topics: Acetaminophen; Bariatric Surgery; Caffeine; Gastric Bypass; Humans; Obesity, Morbid | 2017 |
Comment on: "Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen".
Topics: Acetaminophen; Cytochrome P-450 CYP2E1; Humans; Obesity, Morbid | 2018 |
Author's Reply to Reith: "Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen".
Topics: Acetaminophen; Cytochrome P-450 CYP2E1; Humans; Obesity, Morbid | 2018 |
Multimodal Postoperative Pain Control Is Effective and Reduces Opioid Use After Laparoscopic Roux-en-Y Gastric Bypass.
Topics: Acetaminophen; Administration, Oral; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Celecoxib; | 2019 |
Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen.
Topics: Acetaminophen; Adolescent; Adult; Area Under Curve; Body Mass Index; Cysteine; Cytochrome P-450 CYP2 | 2016 |